| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 29/05/2024 | 14:05 | GlobeNewswire Inc. | Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 | NASDAQ:ALVO | Alvontech |
| 21/05/2024 | 23:15 | GlobeNewswire Inc. | Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update | NASDAQ:ALVO | Alvontech |
| 21/05/2024 | 16:05 | Business Wire | Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK | NASDAQ:ALVO | Alvontech |
| 21/05/2024 | 14:00 | GlobeNewswire Inc. | Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK | NASDAQ:ALVO | Alvontech |
| 21/05/2024 | 13:13 | IH Market News | U.S. Index Futures Open Lower Amid Nasdaq Record, Fed Speeches | NASDAQ:ALVO | Alvontech |
| 21/05/2024 | 02:25 | Business Wire | Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. | NASDAQ:ALVO | Alvontech |
| 13/05/2024 | 14:00 | GlobeNewswire Inc. | Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) | NASDAQ:ALVO | Alvontech |
| 02/05/2024 | 13:15 | GlobeNewswire Inc. | Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 | NASDAQ:ALVO | Alvontech |
| 30/04/2024 | 10:00 | GlobeNewswire Inc. | U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) | NASDAQ:ALVO | Alvontech |
| 24/04/2024 | 10:00 | GlobeNewswire Inc. | Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) | NASDAQ:ALVO | Alvontech |
| 19/04/2024 | 12:10 | GlobeNewswire Inc. | Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) | NASDAQ:ALVO | Alvontech |
| 16/04/2024 | 23:43 | Business Wire | Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 03/04/2024 | 13:41 | GlobeNewswire Inc. | Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 | NASDAQ:ALVO | Alvontech |
| 22/03/2024 | 21:15 | GlobeNewswire Inc. | Alvotech Announces Increase in Number of Own Shares | NASDAQ:ALVO | Alvontech |
| 20/03/2024 | 21:15 | GlobeNewswire Inc. | Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update | NASDAQ:ALVO | Alvontech |
| 20/03/2024 | 12:17 | IH Market News | U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip | NASDAQ:ALVO | Alvontech |
| 05/03/2024 | 22:00 | GlobeNewswire Inc. | Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET | NASDAQ:ALVO | Alvontech |
| 29/02/2024 | 22:05 | GlobeNewswire Inc. | Alvotech Appoints Interim Chief Quality Officer | NASDAQ:ALVO | Alvontech |
| 26/02/2024 | 10:25 | GlobeNewswire Inc. | Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share | NASDAQ:ALVO | Alvontech |
| 24/02/2024 | 02:15 | GlobeNewswire Inc. | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NASDAQ:ALVO | Alvontech |
| 24/02/2024 | 02:15 | Business Wire | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NASDAQ:ALVO | Alvontech |
| 15/02/2024 | 12:30 | GlobeNewswire Inc. | Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 29/01/2024 | 10:00 | GlobeNewswire Inc. | Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® | NASDAQ:ALVO | Alvontech |
| 19/01/2024 | 18:31 | Dow Jones News | Alvotech Shares Climb After FDA Concludes Facility Inspection | NASDAQ:ALVO | Alvontech |
| 19/01/2024 | 17:30 | GlobeNewswire Inc. | Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 | NASDAQ:ALVO | Alvontech |
| 10/01/2024 | 09:30 | GlobeNewswire Inc. | STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara | NASDAQ:ALVO | Alvontech |
| 03/01/2024 | 09:30 | GlobeNewswire Inc. | Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) | NASDAQ:ALVO | Alvontech |
| 29/11/2023 | 10:00 | GlobeNewswire Inc. | Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® | NASDAQ:ALVO | Alvontech |
| 28/11/2023 | 22:15 | GlobeNewswire Inc. | Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update | NASDAQ:ALVO | Alvontech |
| 21/11/2023 | 14:00 | GlobeNewswire Inc. | Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET | NASDAQ:ALVO | Alvontech |